Entero Therapeutics, Inc. (NASDAQ:ENTO) to Post Q2 2024 Earnings of ($1.55) Per Share, Roth Capital Forecasts

Entero Therapeutics, Inc. (NASDAQ:ENTO) – Roth Capital issued their Q2 2024 earnings per share estimates for Entero Therapeutics in a research note issued on Monday, May 20th. Roth Capital analyst J. Aschoff expects that the company will post earnings of ($1.55) per share for the quarter. The consensus estimate for Entero Therapeutics’ current full-year earnings is ($5.39) per share. Roth Capital also issued estimates for Entero Therapeutics’ Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.41) EPS, FY2024 earnings at ($1.13) EPS, FY2025 earnings at ($1.52) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.65) EPS and FY2028 earnings at $0.66 EPS.

Entero Therapeutics Trading Down 4.1 %

Shares of ENTO stock opened at $2.82 on Thursday. Entero Therapeutics has a 1-year low of $2.33 and a 1-year high of $60.00. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.21 and a quick ratio of 1.21.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.